quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:30:00·87d
PRRelease
Arrowhead Pharmaceuticals Inc. logo

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

ARWR· Arrowhead Pharmaceuticals Inc.
Health Care
Original source

Companies

  • ARWR
    Arrowhead Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Apr 21UpdateMorgan Stanley$100.00
  • Jun 5UpdateGoldman$31.00
  • Dec 4UpdateBofA Securities$29.00
  • Sep 19UpdateCitigroup$33.00
  • Jul 21UpdateTD Cowen-
  • May 12UpdateSVB Securities$40.00

Related

  • PR6h
    Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe
  • ANALYST3d
    Arrowhead upgraded by Morgan Stanley with a new price target
  • PR3d
    Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results
  • PR27d
    Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology's 75th Annual Scientific Session and Expo
  • SEC28d
    Amendment: SEC Form SCHEDULE 13G/A filed by Arrowhead Pharmaceuticals Inc.
  • SEC34d
    Arrowhead Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
  • INSIDER45d
    Chief Medical Officer Hamilton James C sold $641,900 worth of shares (10,000 units at $64.19), decreasing direct ownership by 4% to 236,958 units (SEC Form 4)
  • PR59d
    Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022